# How Could the New Attorney General Impact Cannabis Rescheduling? (Newsletter: April 3, 2026) > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/attorney-general-cannabis-policy-impact-rescheduling-2026/ > **Published:** 2026-04-03T16:39:32-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:56:44-04:00 > **Clinical Summary:** Explore how the attorney general cannabis policy impact could shape federal cannabis rescheduling and clinical research in 2026. --- ✦ New CED Clinical Relevance #45 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyResearchMental Health Clinical Summary # Clinical Summary The incoming attorney general’s stance on cannabis policy will significantly influence the trajectory of federal cannabis rescheduling efforts, which currently remain stalled despite growing clinical evidence supporting medical applications. Changes in prosecutorial priorities and Department of Justice resource allocation could either accelerate or impede the rescheduling process, directly affecting clinicians’ ability to prescribe [cannabis-based therapies](https://cedclinic.com/cannabinoids-inhibit-keratinocyte-proliferation-non-cb1-cb2/) and conduct federally funded research. If the new administration prioritizes rescheduling, expanded research opportunities and clearer prescribing guidelines could emerge; conversely, deprioritization would maintain current barriers to clinical investigation and evidence generation. The regulatory environment shaped by the attorney general’s enforcement philosophy will determine whether cannabis remains a Schedule I drug, limiting legitimate medical use, or transitions to a schedule permitting clinical practice and higher-quality evidence development. For clinicians, shifts in federal policy directly impact their ability to recommend cannabis to patients with appropriate indications, access to standardized products, and participation in rigorous clinical trials that could validate therapeutic benefit. Dr. Caplan’s Take “If cannabis remains Schedule I while we’re conducting legitimate [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/), we’re essentially asking physicians to practice medicine with one hand tied behind our backs, and that’s a disservice to patients who could benefit from evidence-based dosing and quality standards.” Clinical Perspective ?️ The potential rescheduling of cannabis under a new attorney general represents a significant regulatory inflection point that could reshape clinical practice, though providers should recognize that legal status and medical evidence do not always move in tandem. Changes in federal scheduling would likely increase research opportunities and reduce regulatory barriers to studying cannabis therapeutics, but current clinical evidence remains mixed regarding efficacy for most conditions outside neuropathic pain and chemotherapy-related nausea. Providers should be cautious about interpreting rescheduling as an endorsement of clinical utility; regulatory change often reflects political and legal considerations rather than conclusive therapeutic benefit. In the meantime, clinicians caring for patients interested in cannabis should maintain evidence-based counseling about potential harms (particularly for developing brains and those at risk for psychosis), document discussions thoroughly given the shifting legal landscape, and stay informed about evolving clinical guidelines as the research environment potentially expands. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+How+could+new+attorney+general+impact+cannabis+rescheduling%3F+%28Newsletter%3A+April+3%2C+2026%29+%40drcaplan&url=https%3A%2F%2Fwww.marijuanamoment.net%2Fhow-could-new-attorney-general-impact-cannabis-rescheduling-newsletter-april-3-2026%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.marijuanamoment.net%2Fhow-could-new-attorney-general-impact-cannabis-rescheduling-newsletter-april-3-2026%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+How+could+new+attorney+general+impact+cannabis+rescheduling%3F+%28Newsletter%3A+April+3%2C+2026%29+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.marijuanamoment.net%2Fhow-could-new-attorney-general-impact-cannabis-rescheduling-newsletter-april-3-2026%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - Marijuana Rescheduling Could Be Impacted If Trump Replaces Bondi As Attorney General … - [Marijuana Rescheduling Could Be Impacted If Trump Replaces Bondi As Attorney General …](https://cedclinic.com/federal-cannabis-rescheduling-impacts-attorney-general-changes/) - [CED Digest: 20 Items — March 20, 2026](https://cedclinic.com/cannabis-clinical-updates-march-20-2026/) 📰 Source: [https://www.marijuanamoment.net/how-could-new-attorney-general-impact-cannabis-rescheduling-newsletter-april-3-2026/](https://www.marijuanamoment.net/how-could-new-attorney-general-impact-cannabis-rescheduling-newsletter-april-3-2026/) Further Reading CED Clinic Blog[Adolescent Cannabis and Mental Health in Teens: A Careful Reading of a Large New Study](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) Evidence Watch[Nose-to-Brain Delivery System for Incorporating Monoterpenes with Anti-Depressant Potential.](https://cedclinic.com/monoterpenes-antidepressant-potential-nose-to-brain-delivery/) Research Digest[Research Digest: 5 Recent Studies – March 25, 2026](https://cedclinic.com/research-digest-recent-studies-march-2026/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Federal Marijuana reclassification could reshape medical research and cannabis industry](https://cedclinic.com/federal-marijuana-rescheduling-medical-research-clinical-impact/) Learn how federal marijuana rescheduling may transform medical research and the cannabis industry landscape. [Read More](https://cedclinic.com/federal-marijuana-rescheduling-medical-research-clinical-impact/) [Cannabis Schedule III Rescheduling Impact on Medical Research and Patients](https://cedclinic.com/cannabis-schedule-iii-rescheduling-research-impact-patients/) Explore the implications of cannabis Schedule III rescheduling on research opportunities and patient care. [Explore Insights](https://cedclinic.com/cannabis-schedule-iii-rescheduling-research-impact-patients/) [How U.S. marijuana reclassification could help cannabis companies – The Detroit News](https://cedclinic.com/marijuana-reclassification-impact-cannabis-companies/) Discover potential benefits of marijuana reclassification for cannabis companies and the broader market. [Learn More](https://cedclinic.com/marijuana-reclassification-impact-cannabis-companies/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).